Among irAEs, irHAEs are one of the most serious adverse events of cancer immunotherapy including PD-1 and PD-L1 inhibitors, but relatively rare, leading to difficulty in early detection for prevention of life-threatening complications [7]. This evidence concerns the gene PDCD1 and cancer.